Stephen J. Freedland, MD

Articles

Final Thoughts on CSPC

July 17th 2024

Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.

Patient Case 2: Metastatic CSPC

July 17th 2024

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA

July 10th 2024

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

The Role of PSA Doubling Time in Risk Assessment

July 10th 2024

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

The EMBARK trial investigating enzalutamide in NM CSPC

July 3rd 2024

Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.

Evolving Treatment Paradigm and NCCN Guideline Updates

July 3rd 2024

Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.

Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

June 26th 2024

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

June 26th 2024

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC

June 26th 2024

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Dr Freedland on Treatment Suspension and HRQoL During the EMBARK Trial in nmHSPC

June 1st 2024

Stephen J. Freedland, MD, discusses the correlation between treatment suspension and HRQoL in patients with nmHSPC who were enrolled on the phase 3 EMBARK trial.

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

December 8th 2023

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Dr. Freedland on Real-World Utility of Enzalutamide in Prostate Cancer

May 12th 2020

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Dr. Freedland on Real-World Utility of Enzalutamide in Prostate Cancer

May 11th 2020

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Dr. Freedland on Real-World Evidence Vs PREVAIL Trial in mCRPC

March 27th 2020

Stephen J. Freedland, MD, discusses how real-world evidence with the use of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) compares with data from the phase III PREVAIL trial.

Dr. Freedland on the Importance of Conducting Real-World Analyses in Prostate Cancer

March 10th 2020

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Dr. Freedland on Standardized PSA Testing in Prostate Cancer

March 6th 2020

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.

Dr. Freedland on a Real-World Analysis of Enzalutamide in mCRPC

February 19th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Dr. Freedland on Diet and Lifestyle Interventions in Patients With Prostate Cancer

March 1st 2018

Stephen J. Freedland, MD, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, professor of surgery, Cedars-Sinai Medical Center, discusses nuanced diet and lifestyle interventions in patients with prostate cancer.

Dr. Freedland on the Association Between Carbohydrates and Prostate Cancer Risk

August 6th 2014

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index, and prostate cancer risk.

Dr. Freedland on Treating Early-Stage Prostate Cancer

October 31st 2012

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.